 SAN DIEGO, Nov. 16, 2020 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals, Inc. Nasdaq: CRNX, a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Peter Trainer, MD, FRCPE to the position of Vice President of Clinical Endocrinology. 